Glaukos Shares Face Pressure Despite Record Quarterly Performance

Glaukos Corporation reported exceptional financial results for its second quarter, yet its stock experienced notable selling pressure in subsequent trading. The market’s reaction stands in contrast to the company’s strong operational metrics and upgraded annual guidance.

Exceptional Quarterly Growth Metrics

For Q2 2025, Glaukos announced consolidated net revenues of $124.1 million, representing a significant 30 percent year-over-year increase. The company’s core U.S. glaucoma business demonstrated even more robust growth, surging 45 percent to reach $72.3 million. The standout performer was clearly iDose TR, the intracameral delivery system that generated approximately $31 million in revenue, demonstrating impressive market adoption.

Although the company reported a net loss of $19.7 million, this figure represents substantial improvement from the $50.5 million loss recorded during the same period last year. Glaukos maintains strong profitability metrics with a gross margin of 78 percent and a non-GAAP margin of approximately 83 percent. The balance sheet remains solid with $278.6 million in liquid assets and no outstanding debt.

Upgraded Outlook and Strategic Advancements

Management responded to the stronger-than-expected performance by raising full-year 2025 revenue guidance. The company now anticipates revenues between $480 million and $486 million, up from the previous range of $475 million to $485 million.

Three key strategic developments underpin this optimistic outlook:

Should investors sell immediately? Or is it worth buying Glaukos?

• iDose TR continues its successful commercial trajectory, transforming glaucoma treatment paradigms
• iStent Infinite received European Union approval, providing access to a $400 million market opportunity
• Epioxa awaits FDA decision scheduled for October 20, 2025

The EU authorization for iStent Infinite establishes Glaukos’s position in the European MIGS market, while the pending FDA verdict on Epioxa represents a substantial potential catalyst for the stock.

Understanding the Stock’s Decline

Despite these positive fundamentals, Glaukos shares declined approximately 5 percent to $90.05 in recent trading. With a market capitalization of $5 billion, the stock now trades below its key technical indicators, including the 50-day moving average of $95.60 and the 200-day moving average of $98.45. Over the past twelve months, the share price has fluctuated between $77.10 and $163.71.

This disconnect between strong operational performance and stock price movement appears rooted in ongoing investor concerns regarding Medicare reimbursement policies. Current regulations limit the use of two MIGS devices in a single procedure, and these restrictions are expected to remain through 2025. Additionally, the company has extended the evaluation period for NCX 1728, a glaucoma treatment being developed in collaboration with Nicox SA.

Whether Glaukos can successfully navigate these regulatory challenges remains a key question for investors. The company’s robust product pipeline and continued commercial success with innovations like iDose TR suggest strong long-term potential, even as short-term market uncertainty persists.